Pyxis Oncology, Inc. (NASDAQ:PYXS) Sees Large Decrease in Short Interest

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average daily trading volume, of 402,636 shares, the days-to-cover ratio is presently 5.6 days.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently bought and sold shares of PYXS. Bank of America Corp DE boosted its holdings in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Pyxis Oncology by 37.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after purchasing an additional 13,550 shares in the last quarter. Vanguard Group Inc. lifted its position in Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after purchasing an additional 14,566 shares during the period. Velan Capital Investment Management LP boosted its holdings in Pyxis Oncology by 37.5% in the 3rd quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after purchasing an additional 15,000 shares in the last quarter. Finally, LPL Financial LLC raised its stake in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after buying an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Analysts Set New Price Targets

PYXS has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Stifel Nicolaus reduced their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research report on Monday, April 13th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Trading Up 1.2%

Pyxis Oncology stock opened at $1.72 on Friday. The stock has a 50 day moving average of $1.55 and a two-hundred day moving average of $2.37. Pyxis Oncology has a twelve month low of $0.97 and a twelve month high of $5.55. The stock has a market capitalization of $108.07 million, a price-to-earnings ratio of -1.33 and a beta of 1.43.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to analysts’ expectations of $0.13 million. Equities analysts predict that Pyxis Oncology will post -1.24 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.